



Margaret Faul

Margaret received her B.Sc. and M.Sc degrees from University College Dublin, Ireland. She then moved to the US where she received her Ph.D. degree in synthetic organic chemistry from Harvard University with Professor David A. Evans. In 1993 Margaret joined the Chemical Process group at Eli Lilly and Company, and in 2003 she moved to Amgen where she is currently the Executive Director in the Process Development organization. At Amgen, Margaret is responsible for the commercial process development and process characterization of all molecules in both the synthetic and biologic Amgen portfolio.

During her 25-year career, Margaret has leveraged her technical experience to support programs across all stages of development from preclinical to commercialization. She has supported the process development and supply of drug substance for clinical trials and commercial products and has significant experience in scale-up and GMP concepts. Margaret has experience working with commercial manufacturing organizations worldwide and an ability to work with partners during licensing activities to ensure seamless integration and development of programs with the partner company. Margaret has a strong knowledge of regulatory and compliance issues as they relate to the development of pharmaceutical products.

Throughout her industrial career at Amgen, Margaret has invested significant effort in evolving a green chemistry culture focused on implementation of greener and more sustainable chemical processes towards the development of novel drug substances. These efforts resulted in Amgen being awarded the Presidential Green Chemistry Challenge Award in 2017 in recognition of their work to promote the environmental and economic benefits of novel green chemistry.

During her career, Margaret has achieved a strong scientific reputation and has invested significantly in supporting the external scientific efforts. She is a member of the Board of Directors of the International Consortium for Innovation and Quality in the Pharmaceutical Industry and Chair of the Enabling Technologies Consortium. Margaret also has a strong publication record being an author/co-author of more than 150 peer-reviewed publications, presentations and patents. Margaret has served as a symposium organizer and session chair for several major process chemistry events and is/has been a member of the editorial boards for *Organic Synthesis*, *Journal of Organic Chemistry* and *Organic and Biomolecular Chemistry*.